87 related articles for article (PubMed ID: 19636264)
1. Severe osteoporosis and high level TSH in a child before the diagnosis of acute lymphoblastic leukemia.
Atas A; Cakmak A; Soran M; Soker M; Varma M
J Pediatr Hematol Oncol; 2009 Aug; 31(8):588-91. PubMed ID: 19636264
[TBL] [Abstract][Full Text] [Related]
2. Idiopathic juvenile osteoporosis.
Krassas GE
Ann N Y Acad Sci; 2000; 900():409-12. PubMed ID: 10818429
[TBL] [Abstract][Full Text] [Related]
3. PTHrP-independent hypercalcemia with increased proinflammatory cytokines and bone resorption in two children with CD19-negative precursor B acute lymphoblastic leukemia.
Niizuma H; Fujii K; Sato A; Fujiwara I; Takeyama J; Imaizumi M
Pediatr Blood Cancer; 2007 Dec; 49(7):990-3. PubMed ID: 16496289
[TBL] [Abstract][Full Text] [Related]
4. [Idiopathic and secondary osteoporosis in childhood].
Rossi F; Perrotta S; Falcone E; Gimigliano F; Iodice M; Vetrella S; Iolascon G
Minerva Pediatr; 2005 Oct; 57(5):203-11. PubMed ID: 16205605
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate treatment of pediatric bone disease.
Speiser PW; Clarson CL; Eugster EA; Kemp SF; Radovick S; Rogol AD; Wilson TA;
Pediatr Endocrinol Rev; 2005 Dec; 3(2):87-96. PubMed ID: 16361982
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of primary osteoporosis in men].
Yamaguchi T; Sugimoto T
Clin Calcium; 2006 Mar; 16(3):474-9. PubMed ID: 16508131
[TBL] [Abstract][Full Text] [Related]
7. [The successful development of bisphosphonates in the therapy of osteoporosis].
Fassbender WJ; Stumpf UC; Kurth A
Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
[TBL] [Abstract][Full Text] [Related]
8. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
Takeuchi Y
Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
[TBL] [Abstract][Full Text] [Related]
9. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
Cole RE
Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
[TBL] [Abstract][Full Text] [Related]
10. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits.
Smith EJ; Little DG; Briody JN; McEvoy A; Smith NC; Eisman JA; Gardiner EM
J Bone Miner Res; 2005 Oct; 20(10):1731-41. PubMed ID: 16160731
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience.
Lethaby C; Wiernikowski J; Sala A; Naronha M; Webber C; Barr RD
J Pediatr Hematol Oncol; 2007 Sep; 29(9):613-6. PubMed ID: 17805035
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and treatment of osteoporosis in nonmetastatic breast cancer].
Eiken PA; Hansen M; Kristensen B; Langdahl BL; Abrahamsen B
Ugeskr Laeger; 2011 Feb; 173(8):577-81. PubMed ID: 21333258
[TBL] [Abstract][Full Text] [Related]
13. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
14. Deficient bone formation in idiopathic juvenile osteoporosis: a histomorphometric study of cancellous iliac bone.
Rauch F; Travers R; Norman ME; Taylor A; Parfitt AM; Glorieux FH
J Bone Miner Res; 2000 May; 15(5):957-63. PubMed ID: 10804027
[TBL] [Abstract][Full Text] [Related]
15. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.
Otrock ZK; Azar ST; Shamseddeen WA; Habr D; Inati A; Koussa S; Mahfouz RA; Taher AT
Ann Hematol; 2006 Sep; 85(9):605-9. PubMed ID: 16830143
[TBL] [Abstract][Full Text] [Related]
16. Just taller or more bone? The impact of growth hormone on osteogenesis imperfecta and idiopathic juvenile osteoporosis.
Wright NM
J Pediatr Endocrinol Metab; 2000 Sep; 13 Suppl 2():999-1002. PubMed ID: 11086654
[TBL] [Abstract][Full Text] [Related]
17. [Perspective for development of parathyroid hormone and related compounds as therapeutic agents for osteoporosis].
Ikeda K; Fukagawa M
Nihon Rinsho; 2005 Oct; 63 Suppl 10():367-71. PubMed ID: 16279664
[No Abstract] [Full Text] [Related]
18. Treatment of osteoporosis/osteopenia in pediatric leukemia and lymphoma.
Bryant ML; Worthington MA; Parsons K
Ann Pharmacother; 2009 Apr; 43(4):714-20. PubMed ID: 19336653
[TBL] [Abstract][Full Text] [Related]
19. [Bisphosphonate therapy for osteoporosis and bone strength].
Kishimoto H
Clin Calcium; 2006 Sep; 16(9):1513-19. PubMed ID: 16951477
[TBL] [Abstract][Full Text] [Related]
20. Fracture risk associated with chronic use of bisphosphonates: evidence today.
Charopoulos I; Orme S; Giannoudis PV
Expert Opin Drug Saf; 2011 Jan; 10(1):67-76. PubMed ID: 21121870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
